further corroborated these findings by verifying miR-16’s direct binding to the VEGF 3’-UTR, suggesting a tumor-suppressive role for miR-16 in MDS development by targeting VEGF (13). The gene discussed is VEGFA; the disease is myelodysplastic syndrome.